Abstract The present study aimed to investigate the effects of N-methyl-D-aspartate (NMDA)-type glutamate receptor agonist, NMDA, on anxiety-like behavior induced by d-opioid receptor agents in rats, using the elevated plus maze instrument. The dorsal hippocampus (CA1) is known to play an important role in anxiety formation and modulation. Bilateral administration of different doses of d-opioid receptor agonist, [D-pen2,5] enkephalin acetate hydrate (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat; 1 mL/rat; 0.5 mL/rat in each side), into CA1 area induced an anxiolytic-like effect, demonstrated by substantial increases in the percent of open arm time (OAT%) and percent of open arm entries (OAE%). Intra-CA1 injection of different doses of d-opioid receptor antagonist, naltrindole hydrochloride (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat), produced significant anxiogenic-like behavior. Furthermore, intra-CA1 administration of NMDA glutamate receptor agonist, NMDA (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/rat, and 0.75 mg/rat), increased the OAT% and OAE%, indicating anxiolytic-like behavior. However, administration of different doses of NMDA glutamatergic antagonist, MK801 (0.125 mg/rat, 0.25 mg/rat, 0.5 mg/ rat, and 1 mg/rat), showed no significant effect on the OAT% but decreased the OAE% significantly. The ineffective dose of NMDA (0.125 mg/rat), when coadministered with enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat), did not decrease the anxiety behavior significantly. An effective dose of NMDA (0.5 mg/rat), in combination with different doses of naltrindole hydrochloride (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat), demonstrated no significant interaction with the OAT%, OAE%, and locomotor activity. These results suggest that CA1 d-opioid and NMDA glutamatergic systems modulate anxiety behaviors in a noninteractive manner.
Introduction
The hippocampus plays an important role in the modulation and regulation of behaviors, such as learning and memory [1] . In addition, role of dorsal hippocampus (CA1) in the modulation of anxiety is crucial [2] . Previous studies have shown that the serotonergic system of the dorsal hippocampus mediates anxiogenic responses, whereas the dorsal hippocampal nicotinic cholinergic system mediates anxiolytic responses [2] .
Glutamate, a main excitatory neurotransmitter of brain, is of great significance in the modulation of behaviors by means of several glutamate receptors. At least three subtypes of excitatory amino acid receptors, named after their preferential agonists, that is, N-methyl-D-aspartate (NMDA), quisqualate, and kinate have been identified [3] . The NMDA receptor, as an ionotropic glutamate receptor, plays an important role in the modulation of behavioral effects of glutamate. Studies demonstrated that the NMDA receptor is involved in the control of anxiety-related behaviors. In several studies conducted in animal models of anxiety, after the administration of agonists of the NMDA receptor, behavioral and anxiolytic effects have been reported [4] .
Opioid peptides are involved in diverse functions, including pain perception, respiration, homeothermy, nutrient intake, and in immune response. Several researches have underscored the role of opioid receptors in regulating baseline anxiety states and related behaviors [5] . Our previous study showed that dorsal hippocampal opioid receptors are involved in the modulation of anxiety-associated behaviors [6] . Furthermore, neurotransmitter systems in different sites across the central nervous system are also involved in the modulation of opioid receptor agonisterelated effects on anxiety and behaviors [7] . Recently, the regulating role of the endogenous opioid system on emotional-like behavior has been tested. Investigations on m-and d-but not k-opioid receptor knockout mice have indicated that the basal levels of anxiety in different models of anxiety are prone to change [8] . Although the d-opioid receptor knockout mice showed anxiogenic-like responses in the elevated plus maze (EPM) and the light-dark box, the mice lacking m-opioid receptors showed lower levels of anxiety in the EPM [8] .
Interactions between opioidergic and glutamatergic systems are reported in the different areas of the brain, such as sensorimotor cortex [9] , striatum [10] , dorsal raphe nucleus [11] , and finally in spinal cord [12] . Opioids inhibit glutamate release in rat periaqueductal gray cells, CA3 area [13] , and also in the CA1 region of the hippocampus [12] . Enkephalin and glutamate regulate the expression of d-opioid receptors in rat cortical astrocytes [14] . Moreover, the opioidergic system inhibits capsaicin-evoked release of glutamate from rat spinal dorsal horn slices [15] .
The opioidergic system inhibits K þ -evoked glutamate release from rat cerebrocortical slices [16] . Current evidences suggest that long-term d-opioid receptor activation may cause alteration in the glial glutamate uptake properties [17] . Furthermore, blocking of d-opioid receptors induces an NMDA receptoredependent excitotoxicity in anoxic turtle cortex [18] . On the other hand, some studies have reported an interaction between d-opioid and NMDA receptors in the development and maintenance of the repeated swim stress-induced thermal hyperalgesia [19] . In the present study, possible interactions of the two systems in the anxiety-like behaviors were investigated.
Methods
The study was carried out at the Biology Department of Islamic Azad University, Karaj Branch, Karaj, Iran, between December 2008 and June 2009. The University Ethics Committee approved the research protocol. All the treatments and behavioral tests were conducted between 3 PM and 6 PM.
Animals
Male Wistar rats from Pasteur Institute (Tehran, Iran), weighing 180e230 g at the time of surgery, were used. The animals were housed four per cage in a room with a 12:12 hour light/dark cycle (lights on 07:00 hours) and controlled temperature (23 AE 1 C), and they had access to food and water ad libitum and were allowed to adapt to the laboratory conditions for at least 1 week before surgery. The rats were handled about 3 minutes each day before behavioral testing. All the experiments were performed between 12:00 hours and 15:00 hours, and each rat was tested only once. Seven animals were used in each experiment.
Stereotaxic surgery and microinjections
The rats were anesthetized intraperitoneally with ketamine hydrochloride (50 mg/kg) and xylazine (4 mg/kg) and placed in a Stoelting stereotaxic instrument (Wood Dale, IL, USA). A stainless steel guide cannula (22 gauge) was implanted in the right and left CA1 regions according to Paxinos [20] . Stereotaxic coordinates for the CA1 regions were as follows: À3.8 mm posterior to bregma, AE2 mm lateral to the midline, and À3 mm ventral of the dorsal surface of the skull. The cannula was fixed to the skull with acrylic dental cement. The animals were allowed 5 days before the test to recover from surgery. The left and right CA1 were infused by means of an internal cannula (27 gauge), terminating 1 mm below the tip of the guides, connected by polyethylene tubing to a 1-mL Hamilton syringe (Bonaduz, GR, Switzerland). On each side, 0.5-mL solution was injected (1 mL/rat) over a 60-second period. The inner cannula was left in place for an additional 60 seconds to allow diffusion of the solution and to reduce the possibility of reflux. Intra-CA1 injections were made 5 minutes before testing.
Plus maze
This wooden, plus-shaped apparatus was elevated to the height of 50 cm. This apparatus was composed of two 50 Â 10-cm open arms and two 50 Â 10 Â 50-cm enclosed arms, each with an open roof. The maze was placed in the center of a quiet and dimly lit room. The rats' behaviors were directly observed using a mirror, suspended at an angle above the maze. Behavioral data were collected by an observer who quietly sat 1 m behind one of the closed arms of the maze, using a time recorder. Five minutes after their respective drug treatment, rats were placed individually in the center of the plus maze, facing one of the closed arms. The observer measured (1) . The total number of arms entered, as well as the total number of closed arms entered, was used as an index of general locomotor activity [21] .
Drugs
The drugs used in the present study were [D-pen2,5]-enkephalin acetate hydrate (d-opioid receptor agonist) and naltrindole hydrochloride (d-opioid receptor antagonist) (Tocris Co., Ballwin, MO, USA); NMDA (NMDA glutamatergic receptor agonist); and MK801(NMDA glutamatergic receptor antagonist) (Sigma Chemical Co., St. Louis, MO, USA).
Drug treatments
Experiment 1: effects of NMDA receptor agonist and antagonist on anxiety behavior Four groups of rats received bilateral dorsal hippocampus injection (intra-CA1) of NMDA receptor agonist NMDA (0.125 mg/rat, 0.25 mg/rat, 0. 5 mg/rat, and 0.75 mg/rat) [22, 23] and four other groups received NMDA receptor antagonist MK801 (0.25 mg/rat, 0.5 mg/rat, 0.75 mg/rat, and 1 mg/rat) [22] and were compared with saline control group. Experiment 2: effects of d-opioid receptor agonist and antagonist on anxiety-like behavior Four groups of rats received bilateral dorsal hippocampus injection (intra-CA1) of selective d receptor agonist enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat) [24, 25] , and four other groups received d receptor antagonist naltrindole hydrochloride (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/ratdintra-CA1) [26, 27] . These rats were thereafter compared with a saline control group. Experiment 3: effects of NMDA in combination with d receptor agonist on anxiety behavior First, five groups of rats received saline (1 mL/ratdintra-CA1). Three minutes later, the first group received saline (1 mL/ ratdintra-CA1), and the other groups received four different doses of enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/ ratdintra-CA1). Five other groups of rats received an intra-CA1 injection of NMDA (0.125 mg/ratdintra-CA1) 3 minutes before injection of saline (1 mL/ratdintra-CA1) or enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/ratdintra-CA1).
Experiment 4: effects of NMDA in combination with d receptor antagonist on anxiety behavior
The first five groups of rats received saline (1 mL/ratdintra-CA1). Three minutes later, the first group received saline (1 mL/ratdintra-CA1), and the other groups received four different doses of naltrindole (0.25 mg/rat, 0.5 mg/rat, 0.75 mg/rat, and 1 mg/ratdintra-CA1). Five other groups of rats received an intra-CA1 injection of NMDA (0.5 mg/ ratdintra-CA1) 3 minutes before injection of saline (1 mL/ ratdintra-CA1) or naltrindole (0.25 mg/rat, 0.5 mg/rat, 0.75 mg/rat, and 1 mg/ratdintra-CA1).
Histology Figure 1 shows the approximate point of the drug injection in CA1. The histological results were plotted on the representative section taken from the rat brain atlas of Paxinos [20] . After the completion of behavioral testing, the animals were killed with an overdose of chloroform. Ink (0.5 mL of 1% aquatic methylene blue solution) was injected into the guide cannulae using 27-gauge injection cannulae that projected a further 0.5 mm ventral to the tip of the guides to aid in histological verification. Brains were removed and fixed in a 10% formalin solution for 48 hours before sectioning. The sections were taken through the brain areas of cannulae placements, and the cannulae Figure 1 . A sample of the drug injection site in dorsal hippocampus (CA1). The sections were taken through the brain areas of cannulae placements, and the cannulae placements were verified using the atlas of Paxinos.
placements were verified using the atlas of Paxinos. Data from the rats with injection sites located outside the hippocampal CA1 area were not used in the analyses. There were seven rats with correct injection site per group.
Statistical analysis
Because data displayed normal distribution and homogeneity of variance, one-way analysis of variance (ANOVA) was used for comparison among the effects of different doses of drugs with vehicle. Two-way ANOVA was used for the evaluation of interactions between drugs. In case the difference was significant, the post hoc analysis (least significant difference) was performed to assess specific group comparisons. Differences with p < 0.05 between experimental groups at each point were considered statistically significant.
Results
Effects of NMDA receptor agonist and antagonist on anxiety behavior (Fig. 3) .
Effects of d-opioid receptor agonists and antagonists on anxiety-like behavior
One-way ANOVA revealed that intra-CA1 injection of dopioid receptor agonist, enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/rat; 1 mL/rat) increased OAT% [F (3,24) Z 4.421, p < 0.05] and OAE% [F (3,24) Z 5.599, p < 0.05] at doses of 1 mg/rat, 2 mg/rat, and 5 mg/rat, indicating the induction of anxiolytic effects. No significant change in the locomotor activity was observed [F (3,24) Z 0.946, p > 0.05] (Fig. 4) .
The intra-CA1 infusions of d-opioid receptor antagonist naltrindole hydrochloride decreased OAT% [F (4,30) Z 5.532, p < 0.05] at doses of 0.5 mg/rat, 1 mg/rat, and 2 mg/rat, and decreased OAE% [F (4,30) Z 5.961, p < 0.05] at doses of 0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat, indicating the induction of anxiogenic effects by naltrindole. No significant change in the locomotor activity was observed [F (4,30) Z 0.431, p > 0.05] (Fig. 5) .
Effects of enkephalin alone or with NMDA on anxiety-like behavior
The effects of intra-CA1 injections of the d receptor agonist, enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and Effects of naltrindole alone or with NMDA on anxiety-like behavior Figure 7 shows the effects of intra-CA1 injections of the d-opioid receptor antagonist naltrindole (0.25 mg/rat, 0.5 mg/rat, 0.75 mg/rat, and 1 mg/ratdintra-CA1) in the presence or absence of NMDA (0.5 mg/rat) on anxiety-like 
Discussion
In this study, effects of hippocampal NMDA glutamatergic system and d-opioidergic receptor agents, and also the possible interactions between these agents in the EPM were investigated. Figure 5 . Effects of bilateral intra-CA1 injection of naltrindole in the elevated plus maze. Rats were treated with either saline (1 mL/rat) or with naltrindole (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/rat). Each bar is mean AE standard error of the mean of percent of open arm time (A), percent of open arm entries (B), or locomotor activity (C)d n Z 7. *p < 0.05 and ** p < 0.01, when compared with the saline-treated rats. CA1 Z dorsal hippocampus region. Figure 6 . The effect of bilateral injection of enkephalin in the presence or absence of NMDA in the elevated plus maze. Rats were injected saline (1 mL/ratdintra-CA1) or enkephalin (1 mg/rat, 2 mg/rat, 5 mg/rat, and 10 mg/ratdintra-CA1) 3 minutes after injection of either saline (1 mL/ratdintra-CA1) or NMDA (0.125 mg/ratdintra-CA1). Each bar is mean AE standard error of the mean of percent of open arm time (A), percent of open arm entries (B), or locomotor activity (C)dn Z 7. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with the saline-treated rats. þp < 0.05 and þþp < 0.01 when compared with the saline-and NMDA-treated rats. CA1 Z dorsal hippocampus region; NMDA Z N-methyl-D-aspartate.
The results obtained from the present study show that intraedorsal hippocampus (intra-CA1) injection of NMDA increased OAT% and OAE%, without any impairment in locomotor functioning in the EPM, indicating the induction of an anxiolytic response by NMDA. Thus, the involvement of NMDA receptor mechanism of dorsal hippocampus in the anxiety-like behavior of rats seems possible.
Several recent investigations about the neurobiology of anxiety have highlighted the role of neurotransmitter glutamate as an important element in anxiety and anxious behavior. The effects of glutamate are mediated through different combinations of ionotropic and metabotropic glutamate receptors and potentially different subunit combinations [28, 29] .
Studies suggest that the hippocampus may be involved in these anxiolytic-like actions of glutamatergic system, because the intrahippocampal injections of LY354740, an mGLU2/3 receptor agonist, produced anxiolytic-like effects in rat models [30, 31] . An investigation carried out by Linden et al. [32] showed that the anxiolytic-like activity of LY354740 was associated with the suppression of EPMinduced c-Fos in the hippocampus of mice.
So far, many efforts have been made to develop compounds that can modulate the function of NMDA receptors by acting within the NMDA receptor complex. Nonetheless, using NMDA antagonists appears to be greatly hampered by their associated adverse effects on anxiety because of interference with receptors throughout the central nervous system and the body [28] . Our results demonstrate that the NMDA receptor antagonist MK801 decreases OAE% without significant change in the OAT% and locomotor activity, indicating an anxiogenic effect by MK801, whereas the anxiolytic-like effects of NMDA receptor antagonists have been exhibited in some previous studies. Studies conducted by Jardim and Stephens demonstrated that the systemic or intra-dorsolateral periaqueductal gray administration of NMDA receptor antagonists produces anxiolytic-like effects in animal anxiety models, such as the EPM, brain aversive electrical stimulation, and the Vogel's punished licking test [33, 34] . Studies showed that the administration of antagonists of NMDA and non-NMDA-type receptors into the basolateral amygdala reduces anxiety in animal models [35] . Therefore, it seems that the major target for systemic injections is likely amygdala rather than the hippocampus region. Moreover, controversial results obtained in different investigations may be attributed to different sites of injections or also the different animal models used.
Our results show that the NMDA antagonist, MK801, had only partial effects on anxiety, whereas NMDA agonist clearly affected anxiety-related behaviors. Because the NMDA agonist is more effective than its antagonist, it might be suggested that there is no active anxiety-related endogenous NMDA receptor activity in the CA1.
Other parts of our experiments indicate that intra-CA1 injection of enkephalin increased both OAT% and OAE% without locomotor impairment in the EPM, indicating the induction of an anxiolytic response by enkephalin. Furthermore, intra-CA1 administration of the d-receptor antagonist naltrindole produced substantial anxiogenic-like effects in the plus maze, without any effect on the locomotor activity. The data show that the opioid receptor system in the hippocampus is involved in the anxiolytic-like behavior.
The important role of the opioidergic system in the modulation of anxiety has been shown recently [36] . Because opioid-deficient mice are more anxious than the normal controls [37] , the anxiety disorders may be related, at least in part, to the deficiency of the endogenous opioid system [36] . Also, d-opioid receptors have been associated with anxiety and depression, because d agonists reduce the immobility of the rats in the forced swimming test [38, 39] . A study carried out by Filliol et al. demonstrated that d-opioid receptor knockout mice show anxiogenic-like response in the EPM and the light-dark box. However, the mice lacking m-opioid receptors exhibit lower levels of Figure 7 . The effect of bilateral injection of naltrindole in the presence or absence of NMDA in the elevated plus maze. Rats were injected saline (1 mL/ratdintra-CA1) or naltrindole (0.25 mg/rat, 0.5 mg/rat, 1 mg/rat, and 2 mg/ratdintra-CA1) 3 minutes after injection of either saline (1 mL/ratdintra-CA1) or NMDA (0.5 mg/ratdintra-CA1). Each bar is mean AE standard error of the mean of percent of open arm time (A), percent of open arm entries (B), or locomotor activity (C)dn Z 7. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with the saline-treated rats. þp < 0.05 when compared with the salineand NMDA-treated rats. CA1 Z dorsal hippocampus region; NMDA Z N-methyl-D-aspartate.
anxiety in the EPM [8] . The study by Sher in 2001 [37] showed that intracerebroventricular microinjections of d-opioid receptor antagonist cause a significant anxiogenic effect in mice [40] .
None of the drugs used in the present study affected the locomotor activity of the rats. Locomotor activity evaluation was included primarily to ensure that the effects of the drugs in the EPM test of anxiety could not be attributed to their activity effects [41] .
In conclusion, the results of the present study demonstrate that the intrahippocampal injections of the NMDA glutamatergic and the d-opioid receptor agents affected anxiety behaviors in the rats. There was, however, no interaction between the NMDA and the enkephalin. Furthermore, the intra-CA1 injections of naltrindole and NMDA showed no interaction between these agents in the modulating effects of anxiety-related behavior. Although interaction between the NMDA glutamatergic and opioidergic systems in the modulation of emotional behaviors has been reported in previous studies, our results show that there are no significant interactions between the two systems.
